A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
Latest Information Update: 13 Nov 2025
At a glance
- Drugs Icotrokinra (Primary)
- Indications Ulcerative colitis
- Focus Registrational; Therapeutic Use
- Acronyms ICONIC-UC
- Sponsors Janssen Research & Development
Most Recent Events
- 06 Oct 2025 Status changed from not yet recruiting to recruiting.
- 03 Oct 2025 New trial record